The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen Melanoma-Associated Antigen A4 (MAGE-A4) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs. The present invention provides T cell receptors (TCRs) that were generated against a MAGE-A4 peptide antigen in the context of MHC (HLA-A2). The unique TCR sequences identified have shown specific binding to the small peptide MAGE-A4 presented in the groove of an HLA molecule and exhibited activation of T cells in a reporter assay.

Described herein are compositions for delivering single-domain antibodies or antigen-binding fragments thereof to a subject. The single-domain antibodies may be therapeutic agents for treatment of a disease or a condition in the subject, such as a disease or a condition of affecting the lungs of the subject. The compositions comprise enucleated cells that are extensively engineered to produce the single-domain antibodies or antigen-binding fragment thereof, and optionally, contain additional components, such as a targeting moiety, immune system evading moiety, or additional therapeutic agents or adjuvants. Methods of producing the compositions described herein are provided, which involve methods of enucleating a parent cell to obtain the enucleated cell comprising the single-domain antibody or antigen-binding fragment thereof. Also provided are kits and methods for using the compositions described herein to treat the disease or a condition by administering one or more of the compositions to the subject.

The present disclosure provides, inter alia, compositions, cell populations and pharmaceutical compositions and methods useful for the treatment of inflammatory diseases or disorders. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via treatment with a CD44 ligand for a period of time sufficient to prime the cells to produce elevated levels of one or more anti-inflammatory or immunomodulatory molecules relative to a native populations of CD44.sup.+ cells. In some embodiments, the compositions, cell populations and pharmaceutical compositions and methods comprise a population of CD44.sup.+ cells modified ex vivo via a treatment that is effective to target cells to sites of inflammation.

Disclosed herein are methods and compositions comprising placental adherent stromal cells for treating viral infections and sequelae thereof.

Hypoimmunogenic cell lines useful in enhancing, invoking and/or stimulating an immune response and methods for their use and production are provided.

The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/or anti-PD-L1 antibody and/or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).

Provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a polyethylene glycol (PEG) receptors and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.

Disclosed herein are methods and compositions comprising placental adherent stromal cells for treating viral infections and sequelae thereof.

The present disclosure provides anti-LILRB2 antibodies or antigen-binding fragments thereof, anti-LILRB2 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.